Intrabio

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for rare and common neurological disorders, as well as ageing and healthspan. It is a leader in the discovery and development of innovative novel drugs for rare neurodegenerative diseases with high unmet medical needs.

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for rare and common neurological disorders, as well as ageing and healthspan. Its investigational lead drug, IB1001, is an orally administered, modified amino acid (N-Acetyl-L-Leucine) with the potential to provide a meaningful advance in the treatment paradigm for rare neurodegenerative diseases. IB1001 has been shown to enter enzyme-controlled pathways to correct metabolic dysfunction, improve lysosomal function, and enhance mitochondrial function/ATP production. IntraBio's product AQNEURSA™ (levacetylleucine) is now FDA approved.

• IB1001

  Investigational lead drug, an orally administered, modified amino acid (N-Acetyl-L-Leucine) for rare neurodegenerative diseases.

• AQNEURSA™ (levacetylleucine)

  FDA approved product.

• 2020.11.24

  Reported2020.11.24

  IntraBio appoints Jim Meyers as president and CEO[3]IntraBio任命Jim Meyers为总裁兼首席执行官finanznachrichten.de

  IntraBio announced that Jim Meyers had been appointed president and chief executive officer; he was to take up the role immediately.

Read more

1. 1Home - IntraBiointrabio.com
2. 2Our Products – IntraBiointrabio.com
3. 3IntraBio任命Jim Meyers为总裁兼首席执行官finanznachrichten.de